secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001854270-23-000103
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio extends cash runway into Q4 2024 via GeneFab deal, Q2 net loss $18.7M
-------------------------------------------------------------------------------

- GeneFab transaction provides up to $38M in cash by end of 2025; extends cash runway into Q4 2024.
- IND for SENTI-202 (Logic Gated CAR-NK for AML) on track for 2H 2023; Phase 1 enrollment expected 2024.
- Cash, equivalents & short-term investments $59.6M as of June 30, 2023.
- Q2 net loss $18.7M ($0.42/share); R&D $11.0M (up from $9.2M), G&A $9.6M (down from $13.9M).
- Senti subleases Alameda cGMP facility to GeneFab; co-founder Philip Lee named GeneFab CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/0001854270-23-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/snti-20230811.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer